Skip to content

Study · Non-randomized trial · n = 9 · 2020

5 results

Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders.

Abbara A, Eng PC, Phylactou M, Clarke SA, Richardson R, Sykes CM, Phumsatitpong C, Mills E, Modi M, Izzi-Engbeaya C, Papadopoulou D, Purugganan K and 12 more

Show all authors

Jayasena CN, Webber L, Salim R, Owen B, Bech P, Comninos AN, McArdle CA, Voliotis M, Tsaneva-Atanasova K, Moenter S, Hanyaloglu A, Dhillo WS

The Journal of clinical investigation1 Dec 2020Cited by 73 (Europe PMC)

PMID33196464 (opens in a new tab)PMCIDPMC7685751 (opens in a new tab)DOI10.1172/jci139681 (opens in a new tab)PepBankPUB-33196464
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    In healthy women, the amplitude of the LH rise after kisspeptin‑54 was similar to that after MVT-602.

    In plain wordsIn healthy women, kisspeptin‑54 raised luteinizing hormone by a similar amount as the new compound MVT-602.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    No significant changeAmplitude of LH rise after kisspeptin-54 versus MVT-602 in healthy women
    Study

    n = 9

    Comparator
    MVT-602
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    9.6 nmol/kgAs given in this study (human).

    Source sentences

    Summary
    In healthy women, the amplitude of luteinizing hormone (LH) rise was similar to that after KP54
    1 context sentence
    Summary · context
    We determined the pharmacokinetic and pharmacodynamic properties of MVT-602 (doses 0.01 and 0.03 nmol/kg) versus KP54 (9.6 nmol/kg) in the follicular phase of healthy women (n = 9), and in women with polycystic ovary syndrome (PCOS; n = 6) or hypothalamic amenorrhea (HA; n = 6).
  2. 02HumanNon-randomized trialActivity measurement

    In healthy women, the LH rise after kisspeptin‑54 peaked earlier than after MVT-602 (4.7 versus 21.4 hours).

    In plain wordsIn healthy women, luteinizing hormone peaked sooner after kisspeptin‑54 than after the new compound MVT-602.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseTime to LH peak after kisspeptin-54 versus MVT-602 in healthy women
    Study

    n = 9

    Comparator
    MVT-602
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    9.6 nmol/kgAs given in this study (human).

    Measurements

    Time to LH peak
    4.7 hours
    kisspeptin-54
    Time to LH peak
    21.4 hours
    MVT-602

    Source sentences

    Summary
    but peaked later (21.4 vs. 4.7 hours; P = 0.0002)
    1 context sentence
    Summary · context
    We determined the pharmacokinetic and pharmacodynamic properties of MVT-602 (doses 0.01 and 0.03 nmol/kg) versus KP54 (9.6 nmol/kg) in the follicular phase of healthy women (n = 9), and in women with polycystic ovary syndrome (PCOS; n = 6) or hypothalamic amenorrhea (HA; n = 6).
  3. 03HumanNon-randomized trialActivity measurement

    In healthy women, LH exposure (AUC) after kisspeptin‑54 was lower than after MVT-602 (38.5 versus 169.0 IU h/L).

    In plain wordsIn healthy women, kisspeptin‑54 gave less total luteinizing hormone exposure than the new compound MVT-602.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseLH exposure (AUC) after kisspeptin-54 versus MVT-602 in healthy women
    Study

    n = 9

    Comparator
    MVT-602
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    9.6 nmol/kgAs given in this study (human).

    Measurements

    LH exposure AUC
    38.5 IU∙h/L
    kisspeptin-54
    LH exposure AUC
    169 IU∙h/L
    MVT-602

    Source sentences

    Summary
    with correspondingly increased AUC of LH exposure (169.0 vs. 38.5 IU∙h/L; P = 0.0058).
    1 context sentence
    Summary · context
    We determined the pharmacokinetic and pharmacodynamic properties of MVT-602 (doses 0.01 and 0.03 nmol/kg) versus KP54 (9.6 nmol/kg) in the follicular phase of healthy women (n = 9), and in women with polycystic ovary syndrome (PCOS; n = 6) or hypothalamic amenorrhea (HA; n = 6).
  4. 04LabEx vivo tissueActivity measurement

    In brain slices, GnRH neuron firing lasted a shorter time with kisspeptin‑54 than with MVT-602 (55 versus 115 minutes).

    In plain wordsIn lab tests on brain slices, GnRH neurons fired for a shorter time with kisspeptin‑54 than with the new compound MVT-602.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseDuration of GnRH neuron firing in brain slices
    Study

    n: not reported in source

    Brain slices
    Comparator
    MVT-602
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Duration of GnRH neuron firing
    55 minutes
    kisspeptin-54
    Duration of GnRH neuron firing
    115 minutes
    MVT-602

    Source sentences

    Summary
    a longer duration of GnRH neuron firing than KP54 (115 vs. 55 minutes; P = 0.0012)
    1 context sentence
    Summary · context
    Further, we investigated their effects on KISS1R-mediated inositol monophosphate (IP1) and Ca2+ signaling in cell lines and on action potential firing of GnRH neurons in brain slices
  5. 05LabIn vitro (cells)Activity measurement

    In cell lines, kisspeptin‑54 induced less potent KISS1R-mediated IP1 accumulation than MVT-602.

    In plain wordsIn cells, kisspeptin‑54 switched on its receptor less strongly than the new compound MVT-602.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseKISS1R-mediated IP1 accumulation in cell lines
    Study

    n: not reported in source

    Cell lines
    Comparator
    MVT-602
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MVT-602 induced more potent signaling of KISS1R-mediated IP1 accumulation
    1 context sentence
    Summary · context
    Further, we investigated their effects on KISS1R-mediated inositol monophosphate (IP1) and Ca2+ signaling in cell lines and on action potential firing of GnRH neurons in brain slices

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.